抗病毒药物治疗重症流感的系统评价与随机对照试验网络Meta分析
该系统评价与网络Meta分析检索截至2023年9月20日的随机对照试验,纳入8项试验共1424例住院重症流感患者,其中6项进入网络Meta分析。与安慰剂或标准治疗相比,奥司他韦和帕拉米韦可能缩短季节性流感住院时间,但证据确定性低;所有抗病毒药物对死亡率和其他重要结局的影响非常不确定。
要点
- 与安慰剂或标准治疗相比,奥司他韦缩短季节性流感住院时间平均差-1.63天(95%CI -2.81至-0.45),证据确定性低。
- 帕拉米韦缩短季节性流感住院时间平均差-1.73天(95%CI -3.33至-0.13),证据确定性低。
- 奥司他韦、帕拉米韦和扎那米韦对不良事件或严重不良事件无差异,证据确定性极低。
核心结论
- 在住院重症流感患者中,与标准治疗或安慰剂相比,奥司他韦和帕拉米韦可能缩短住院时间,但证据确定性低。
- 由于随机对照试验数据稀缺,所有抗病毒药物对死亡率和其他重要患者结局的影响非常不确定。
研究设计与样本
- 系统评价与网络Meta分析,检索MEDLINE、Embase、Cochrane CENTRAL、CINAHL、Global Health、Epistemonikos和ClinicalTrials.gov截至2023年9月20日的随机对照试验。
- 纳入8项试验共1424例住院疑似或实验室确诊流感患者,其中6项纳入网络Meta分析。
- 采用频率学网络Meta分析和GRADE方法评估证据确定性,PROSPERO注册号CRD42023456650。
主要发现
- 与安慰剂或标准治疗相比,奥司他韦缩短季节性流感住院时间平均差-1.63天(95%CI -2.81至-0.45),证据确定性低。
- 与安慰剂或标准治疗相比,帕拉米韦缩短季节性流感住院时间平均差-1.73天(95%CI -3.33至-0.13),证据确定性低。
- 与标准治疗相比,奥司他韦对症状缓解时间平均差0.34天(95%CI -0.86至1.54),证据确定性低。
- 与标准治疗相比,帕拉米韦对症状缓解时间平均差-0.05天(95%CI -0.69至0.59),证据确定性低。
- 奥司他韦、帕拉米韦和扎那米韦对不良事件或严重不良事件无差异,证据确定性极低。
关键数值与推荐
- 奥司他韦对比安慰剂或标准治疗:住院时间平均差-1.63天(95%CI -2.81至-0.45),证据确定性低。
- 帕拉米韦对比安慰剂或标准治疗:住院时间平均差-1.73天(95%CI -3.33至-0.13),证据确定性低。
- 奥司他韦对比标准治疗:症状缓解时间平均差0.34天(95%CI -0.86至1.54),证据确定性低。
- 帕拉米韦对比标准治疗:症状缓解时间平均差-0.05天(95%CI -0.69至0.59),证据确定性低。
- 奥司他韦、帕拉米韦或扎那米韦对比安慰剂或标准治疗对死亡率的影响证据确定性极低。
临床怎么用
- 在住院重症流感患者中,与标准治疗或安慰剂相比,奥司他韦和帕拉米韦可能缩短住院时间,但证据确定性低。
- 所有抗病毒药物对死亡率和其他重要患者结局的影响非常不确定。
局限性
- 由于符合条件的试验数量少,无法检验发表偏倚。
- 奥司他韦、帕拉米韦或扎那米韦对死亡率的影响证据确定性极低。
- 抗病毒药物对重症流感患者其他结局的影响仍存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal antiviral drug for treatment of severe influenza remains unclear. To support updated WHO influenza clinical guidelines, this systematic review and network meta-analysis evaluated antivirals for treatment of patients with severe influenza. METHODS: We systematically searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Global Health, Epistemonikos, and ClinicalTrials.gov for randomised controlled trials published up to Sept 20, 2023, that enrolled hospitalised patients with suspected or laboratory-confirmed influenza and compared direct-acting influenza antivirals against placebo, standard care, or another antiviral. Pairs of coauthors independently extracted data on study characteristics, patient characteristics, antiviral characteristics, and outcomes, with discrepancies resolved by discussion or by a third coauthor. Key outcomes of interest were time to alleviation of symptoms, duration of hospitalisation, admission to intensive care unit, progression to invasive mechanical ventilation, duration of mechanical ventilation, mortality, hospital discharge destination, emergence of antiviral resistance, adverse events, adverse events related to treatments, and serious adverse events. We conducted frequentist network meta-analyses to summarise the evidence and evaluated the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. This study is registered with PROSPERO, CRD42023456650. FINDINGS: Of 11 878 records identified by our search, eight trials with 1424 participants (mean age 36-60 years for trials that reported mean or median age; 43-78% male patients) were included in this systematic review, of which six were included in the network meta-analysis. The effects of oseltamivir, peramivir, or zanamivir on mortality compared with placebo or standard care without placebo for seasonal and zoonotic influenza were of very low certainty. Compared with placebo or standard care, we found low certainty evidence that duration of hospitalisation for seasonal influenza was reduced with oseltamivir (mean difference -1·63 days, 95% CI -2·81 to -0·45) and peramivir (-1·73 days, -3·33 to -0·13). Compared with standard care, there was little or no difference in time to alleviation of symptoms with oseltamivir (0·34 days, -0·86 to 1·54; low certainty evidence) or peramivir (-0·05 days, -0·69 to 0·59; low certainty evidence). There were no differences in adverse events or serious adverse events with oseltamivir, peramivir, and zanamivir (very low certainty evidence). Uncertainty remains about the effects of antivirals on other outcomes for patients with severe influenza. Due to the small number of eligible trials, we could not test for publication bias. INTERPRETATION: In hospitalised patients with severe influenza, oseltamivir and peramivir might reduce duration of hospitalisation compared with standard care or placebo, although the certainty of evidence is low. The effects of all antivirals on mortality and other important patient outcomes are very uncertain due to scarce data from randomised controlled trials. FUNDING: World Health Organization.
引用
- Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 39181595. doi:10.1016/S0140-6736(24)01307-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。